238 related articles for article (PubMed ID: 22588779)
1. Development of treatment strategies for advanced neuroblastoma.
Hara J
Int J Clin Oncol; 2012 Jun; 17(3):196-203. PubMed ID: 22588779
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
Bresler SC; Wood AC; Haglund EA; Courtright J; Belcastro LT; Plegaria JS; Cole K; Toporovskaya Y; Zhao H; Carpenter EL; Christensen JG; Maris JM; Lemmon MA; Mossé YP
Sci Transl Med; 2011 Nov; 3(108):108ra114. PubMed ID: 22072639
[TBL] [Abstract][Full Text] [Related]
3. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
4. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
5. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
[TBL] [Abstract][Full Text] [Related]
6. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.
Berry T; Luther W; Bhatnagar N; Jamin Y; Poon E; Sanda T; Pei D; Sharma B; Vetharoy WR; Hallsworth A; Ahmad Z; Barker K; Moreau L; Webber H; Wang W; Liu Q; Perez-Atayde A; Rodig S; Cheung NK; Raynaud F; Hallberg B; Robinson SP; Gray NS; Pearson AD; Eccles SA; Chesler L; George RE
Cancer Cell; 2012 Jul; 22(1):117-30. PubMed ID: 22789543
[TBL] [Abstract][Full Text] [Related]
7. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
8. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
10. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma.
Carpenter EL; Haglund EA; Mace EM; Deng D; Martinez D; Wood AC; Chow AK; Weiser DA; Belcastro LT; Winter C; Bresler SC; Vigny M; Mazot P; Asgharzadeh S; Seeger RC; Zhao H; Guo R; Christensen JG; Orange JS; Pawel BR; Lemmon MA; Mossé YP
Oncogene; 2012 Nov; 31(46):4859-67. PubMed ID: 22266870
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
12. Promising therapeutic targets in neuroblastoma.
Matthay KK; George RE; Yu AL
Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
[TBL] [Abstract][Full Text] [Related]
13. Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
Schönherr C; Ruuth K; Yamazaki Y; Eriksson T; Christensen J; Palmer RH; Hallberg B
Biochem J; 2011 Dec; 440(3):405-13. PubMed ID: 21838707
[TBL] [Abstract][Full Text] [Related]
14. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
15. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
16. ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.
Ueda T; Nakata Y; Yamasaki N; Oda H; Sentani K; Kanai A; Onishi N; Ikeda K; Sera Y; Honda ZI; Tanaka K; Sata M; Ogawa S; Yasui W; Saya H; Takita J; Honda H
Oncogene; 2016 Aug; 35(34):4447-58. PubMed ID: 26829053
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma.
Krytska K; Ryles HT; Sano R; Raman P; Infarinato NR; Hansel TD; Makena MR; Song MM; Reynolds CP; Mossé YP
Clin Cancer Res; 2016 Feb; 22(4):948-60. PubMed ID: 26438783
[TBL] [Abstract][Full Text] [Related]
18. Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.
Najem S; Langemann D; Appl B; Trochimiuk M; Hundsdoerfer P; Reinshagen K; Eschenburg G
Oncotarget; 2016 Nov; 7(45):72634-72653. PubMed ID: 27655666
[TBL] [Abstract][Full Text] [Related]
19. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]